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Familial Associations in Testicular 
Cancer with Other Cancers
Luyao Zhang1, Hongyao Yu1, Otto Hemminki2,3, Asta Försti1,4, Kristina Sundquist4,5,6 & 
Kari Hemminki1,4
Familial risks for testicular cancer (TC) are among the highest of all cancers. However, data are limited 
for histological types of TC and for possible familial associations of TC with other cancers. We used 
the nationwide Swedish Family-Cancer Database for years 1958 to 2015 to analyse familial relative 
risks (RR) for 11,138 TC patients when first-degree relatives were diagnosed with TC or other cancer in 
reference to those without a family history. A total of 191 familial TCs were found, which accounted 
for 2.0% of all TC. The RR was 5.06 when one family member was diagnosed with TC with no significant 
difference between seminoma and nonseminoma. However, the risk for nonseminoma was 33.59 when 
two family members were affected. Internally consistent familial associations of TC, particularly of 
seminoma, were found with breast and nervous system cancers and melanoma. Individual significant 
associations were found for a number of sites, including ovarian, endometrial and prostate cancers. 
Our results suggest that nonseminoma may have a stronger genetic background than seminoma but 
seminoma shares more familial associations with discordant cancers. Clustering of TC with hormone-
dependent cancers of the breast, ovary, endometrium and prostate may suggest mechanistic links and 
possibly gene-environment interactions.
The incidence of testicular cancer (TC) varies with ethnic origin and with economic state, the incidence being 
highest in developed countries and lowest in developing countries1. In Europe, the incidence of TC has dra-
matically increased, concomitantly with an equally dramatic decrease in mortality2,3. Differences in incidence 
between the countries have been among the largest for any cancer. The increasing trend has been described as 
a birth cohort effect but in the high-incidence Scandinavian countries the increase has leveled off2,4. Precursor 
lesions of TC are thought to arise and accumulate as a result of aberrant fetal gonocyte development and these 
in-situ lesions gain invasive phenotype in early adulthood5,6. Individual risk factors of TC include cryptorchidism, 
hypospadias, inguinal hernia, subfertility and other lower risk birth-related factors7,8. Some of these factors are 
understood to be related to androgen insufficiency6. Environmental pollutants have been associated with the risk 
of TC; e.g. the type of organochlorine compounds among endocrine disruptive chemicals6,8. The role of environ-
mental factors was documented among low-risk Finnish immigrants to Sweden whose TC incidence was only 
0.45 of the Swedish rate9. The risk of TC in Sweden-born sons of Finnish immigrant parents was no longer differ-
ent from native Swedes, which implies a strong environmental influence in spite of the 100% Finnish genotype9. 
In a family study on cancer etiology, TC was found to be the cancer with the highest proportion of childhood 
shared environmental effects among all assessed causes10. These results combined suggest that environmental 
factors during childhood and adolescence affect TC risk6,11. Finding these factors and their possible interactions 
with host genetic background would likely help to resolve the issue of increasing incidence trends.
Familial risk of TC is among the highest of all cancers but the risk is significantly higher if the affected 
family member is a brother (6.94) rather than a father (3.90), which is likely related to birth cohort effects12. 
Approximately 1.8% of TC patients have a father or a sibling diagnosed with TC12. According to a Nordic TC 
study, the risk of seminoma in brothers (SIR 4.2) was not different from the risk of all TC in brothers (4.1)13. 
TC has been shown to be associated with other (discordant) cancers in families including lung, kidney and 
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oesophageal cancers, melanoma, leukaemia and non-Hodgkin lymphomas14,15. Our previous study covered the 
years 1958 to 2002 and used data from the Swedish Family-Cancer Database14. As we have recently updated the 
database with cancers up to the year 2015, we decided to revisit, here in this study, familial associations of 11,138 
TCs with TC and discordant cancers.
Results
We identified a total of 11,138 TC of which 9711 were identified in offspring generations used in the RR calcula-
tions. Seminomas (6120) outnumbered nonseminomas (4729) in the total population and among the offspring 
generations (5133 and 4391). The median diagnostic ages for seminoma were higher (38 years) than for nonsemi-
noma (29 years) for all, and in the offspring generations these were 36 and 28 years respectively. All cancers in the 
database amounted to 1.96 million, of which 701,617 were diagnosed in the offspring generations.
Table 1 shows familial risk for TC in sons when a first-degree family member was also diagnosed with TC. A 
total of 191 familial TCs were found in the offspring generation, which accounted for 2.0% of all TC (191/9711). 
RR was 5.06 when one proband was diagnosed with TC and it was 18.23 when two probands were affected. RR 
was 5.55 for seminoma and 4.46 for nonseminoma when one proband was diagnosed with TC. The risk for non-
seminoma was 33.59 when two probands were diagnosed with TC; however these were only 4 cases. The results 
were essentially similar in the reverse order analysis: risk for TC in sons when family members were diagnosed 
with seminoma or nonseminoma (lower two lines in Table 1). The risk of TC was 96.78 when two family members 
were diagnosed with nonseminoma.
Table 2 shows the risk for TC in sons depending on cancers in their family members, and in reverse order, 
the risk of cancer in the offspring generation when family members were diagnosed with testicular cancers. At 
least 20 testicular cancers had to be recorded with any cancer in relatives for the site to be listed. The RR for TC 
was increased when family members were diagnosed with lung (1.11), breast (1.09) and nervous system (1.17) 
cancer and with melanoma (1.24). TC risk was increased to 1.12 when family members were diagnosed with any 
cancer. In the reverse order, risk for any cancer in offspring when family members were diagnosed with TC, the 
results remained significant for breast cancer and melanoma while pancreatic and nervous system cancers lost 
significance. However, a new association of prostate cancer with TC (RR 1.15) emerged. We also carried out an 
analysis of familial risk according to the number of cancers diagnosed in a family, similar to Table 1 (data not 
shown). The only significant association was the RR for ovarian cancer in families of two TC patients (3 families, 
RR 3.49, 95%CI 1.13–10.84).
In Table 3, results are shown for testicular seminoma. Seminoma was associated with the same cancers as all 
TC, and additionally with pancreatic (1.25) and endometrial cancers (1.25) and with Hodgkin lymphoma (1.48). 
The RR of 1.18 for association of seminoma with all cancer was higher than that for all TC. Only two specific asso-
ciations were found in the reverse analysis; RR was 1.16 for prostate cancer and it was 1.28 for melanoma. When 
analyses were conducted by number of cases in family members (data not shown), risk of nervous system cancer 
was increased to 4.47 in two families with two patients diagnosed with seminoma (95% CI 1.12–17.88), and risk 
of non-Hodgkin lymphoma was increased to 5.34 in two families with two patients diagnosed with seminoma 
(95% CI 1.33–21.34).
Analyses were also carried out for nonseminoma (data not shown). RRs for nonseminoma were not increased 
with any discordant cancer. However, prostate cancer was increased to 1.15 when 201 sons were diagnosed with 
nonseminoma (1.00–1.32), and other male genital cancers were increased to 2.36 when six sons were diagnosed 
with nonseminoma (1.06–5.26). All cancers were increased to 1.07 when 1245 sons were diagnosed with non-
seminoma (1.01–1.13).
Discussion
TC has been associated with some other cancers as described in the introduction but the advantage of the present 
study is its size and its design in aiming at internal validation of the results in partially independent two-way anal-
yses. We could show that all testicular cancers were associated with breast cancer and melanoma in both of the 
two-way analyses. Single significant associations were found with lung, ovarian, prostate and nervous system can-
cers. Most site-specific associations of TC were for seminoma, which was associated with melanoma in two ways, 
and with nervous system cancer in two different family types. Associations of seminoma with individual signif-
icant sites included pancreatic, lung, breast, endometrial and prostate cancers and Hodgkin and non-Hodgkin 
Testicular cancer 
histology
Cases with negative 
family history
Cases with 1 FDR Cases with 2 FDRs
Cases RR 95%CI Cases RR 95%CI
Histology in sons
Seminoma 5024 108 5.55 4.59–6.72 1 6.69 0.94–47.52
Non-seminoma 4313 74 4.46 3.54–5.61 4 33.59 12.60–89.56
Histology in relatives
Seminoma 9606 104 4.96 4.09–6.02 1 11.91 1.68–84.58
Non-seminoma 9630 77 4.92 3.93–6.15 4 96.78 36.31–257.94
All testicular cancer 9520 186 5.06 4.38–5.86 5 18.23 7.59–43.81
Table 1. Familial risks for histology-specific testicular cancer (TC). Bolding of RRs shows that 95%CI does not 
include 1.00. FDRs = first degree relatives. RR = relative risk. CI = confidence interval.
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lymphomas. Site-specific associations of nonseminoma only included single significant results with prostate and 
other male genital cancers. Seminoma showed several discordant associations with other cancers, which may be 
related to an 8-year later onset compared to nonseminoma and underlying mechanistic differences.
Single discordant familial associations, listed above, may be of interest but they may also be chance findings 
and thus need to be confirmed in independent settings. Associations of TC with breast and nervous system 
cancers and melanoma were confirmed in at least two separate analyses and only the association with mela-
noma was reported previously14,15. It, however, appears noteworthy that, in addition to breast cancer, other 
hormone-dependent female sites were associated with TC in single analyses including ovarian and endometrial 
cancers, and prostate cancer was an associated male site. These are common cancers and the magnitude of rela-
tive risk was rather modest. It may, however, be premature to consider such a clustering of hormone-dependent 
cancers to be fortuitous.
Although concordant familial risks for TC are well-known, the present results contributed to the notion that 
nonseminoma appeared to be more genetically predisposed than seminoma because the risks were very high in 
families where more than two males were affected but case numbers were few5,6,13. Genome-wide association 
studies (GWAS) have identified some 50 single nucleotide polymorphisms (SNPs), which increased the risk of 
TC and many of these suggest disruption of developmental transcriptional regulation of germ cell differentiation 
as a basis of TC susceptibility16,17. It is, however, not well-known if SNPs may differentiate risks of seminoma and 
nonseminoma. The involved pathways cover KIT/KITLG/MAPK signalling, telomerase function, microtubule 
assembly and DNA damage repair16. The most prominent gene is KITLG that shows an allelic risk of 2.55 with 
a high population frequency of 0.8 for the risk allele18. The gene encodes the ligand for tyrosine-kinase KIT, 
which is commonly somatically mutated in seminomas. It has been calculated for 39 independent SNPs that these 
accounted for 37% of the (father-to-son) familial risk of TC17. The calculated polygenic risk score for men in the 
top 1% of genetic risk have a risk of 14, translating to a 7% lifetime risk of TC16. These data can be compared with 
our lifetime risk calculations in the Nordic familial setting13. The lifetime risk in the population was 0.6% and it 
was 2.3% for the brother of an affected individual, increasing to 10.3% for persons with multiple affected family 
members. As most of the present familial cases (2% of all TC) were affected brothers. Therefore, one can conclude 
that empirical familial risk and polygenic risk scores only partially overlap.
In summary, nonseminoma appeared to show higher familial associations with TC than seminoma but semi-
noma had many more familial associations with other cancer than nonseminoma. Associations of TC with breast 
and nervous system cancers and melanoma were internally consistent and mostly novel. Clustering of TC with 








Relatives with testicular cancers
Any FDRs Any FDRs
Cases RR 95%CI Cases RR 95%CI
Upper aerodigestive tract 9620 91 0.84 0.68–1.03 14604 49 0.85 0.64–1.12
Stomach 9605 106 0.76 0.63–0.92 10633 29 0.69 0.48–1.00
Colorectum 9157 554 1.06 0.97–1.15 61007 246 1.00 0.88–1.13
Liver 9620 91 0.81 0.66–1.00 11383 40 0.90 0.66–1.23
Pancreas 9575 136 1.16 0.98–1.37 12414 63 1.27 0.99–1.63
Lung 9312 399 1.11 1.00–1.23 45724 187 1.04 0.90–1.21
Breast (female and male) 8955 756 1.09 1.01–1.17 117258 544 1.09 1.00–1.18
Cervix 9619 92 0.96 0.79–1.18 13355 52 0.94 0.71–1.23
Endometrium 9565 146 1.09 0.92–1.28 18086 67 0.89 0.70–1.14
Ovary 9590 121 1.12 0.94–1.34 15388 67 1.03 0.81–1.31
Prostate 8877 834 1.03 0.96–1.11 104329 497 1.15 1.05–1.25
Kidney 9593 118 0.86 0.72–1.03 16093 62 0.96 0.75–1.23
Urinary bladder 9475 236 1.05 0.92–1.19 24819 101 1.03 0.85–1.25
Melanoma 9426 285 1.24 1.10–1.40 41537 201 1.16 1.01–1.33
Skin 9524 187 0.87 0.77–1.02 21917 85 0.98 0.79–1.21
Nervous system 9497 214 1.17 1.02–1.34 32146 140 1.07 0.90–1.26
Thyroid glands 9658 53 1.08 0.83–1.42 8640 36 1.02 0.73–1.41
Endocrine glands 9623 88 0.91 0.74–1.12 14964 53 0.85 0.65–1.12
Connective tissue 9673 38 1.07 0.78–1.47 5549 22 0.98 0.65–1.49
Non-Hodgkin lymphoma 9546 165 1.01 0.87–1.18 23160 103 1.10 0.91–1.34
Hodgkin lymphoma 9682 29 0.93 0.64–1.34 6185 17 0.68 0.42–1.10
Myeloma 9650 61 0.93 0.72–1.20 7031 27 0.95 0.65–1.38
Leukemia 9567 144 0.93 0.79–1.10 23342 76 0.82 0.65–1.03
CUP1 9567 144 1.00 0.85–1.18 15566 61 0.98 0.76–1.26
All (including testis) 5521 4190 1.12 1.07–1.16 698512 3101 1.09 1.05–1.13
Table 2. Risk of testicular cancer in sons when family members were diagnosed with any cancer. Bolding of 
RRs shows that 95%CI does not include 1.00. CUP1 = cancer of unknown primary. FDRs = first degree relatives. 
RR = relative risk. CI = confidence interval.
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hormone-dependent cancers of the breast, ovary, endometrium and prostate may have pathophysiological under-
pinnings, which could be related to interactions of endocrine disruptive chemicals or other unknown environ-
mental factors with the host genetic background6,8.
Subjects and Methods
In the Swedish “Multigeneration Register” individuals who were born in Sweden in 1932 and onwards are reg-
istered with their parents. We define these as the offspring and parental generation, respectively19. The Swedish 
“Multigeneration Register” was linked by the individually unique national registration number to the Cancer 
Registry for the years 1958–2015 to make the basis of the Family-Cancer Database. In the Database families are 
organized in subsequent generations. The Swedish personal number is issued to all permanent residents upon 
birth or immigration to Sweden. The completeness of the cancer registry is considered to be over 90%20. The 
cancer site is registered using diagnostic codes according to the 7th (and later) revisions of the International 
Classification of Diseases (ICD-7). Patients diagnosed with TC were identified as were all other cancers in family 
members. The histological classification of TCs was used, as present in the Cancer Registry, to define seminoma 
and non-seminoma.
Relative risks (RRs) were used to measure cancer risks for TC in the offspring generations according to occur-
rence of cancers in their first-degree family members (parents, siblings or children). The parental generation 
born before 1932 was diagnosed with 1427 TC and served as probands only and were not used for person-year 
calculations. In one family TCs were diagnosed in three generations, and the person in the middle generation was 
entered separately as a case and a proband. In the reverse analysis, RR was calculated for cancer in offspring when 
family members were diagnosed with TC. These two types of analyses were partially independent, particularly for 
discordant cancers, and positive results in both analyses provided strong support for a true association. Follow-up 
was started for each offspring at birth, immigration or January 1st, 1958, whichever came latest. Follow-up was 
terminated on diagnosis of first cancer, death, emigration, or the closing date of the study, which was December 
31st, 2015. Parents’ ages were not limited but sons were 0 to 83 years of age; siblings could be defined only in the 
offspring generation.
Poisson regression modeling was employed to estimate RRs and corresponding 95% confidence intervals 
(CI). Potential confounders, including sex, age group (5-year bands), period (5-year bands), socioeconomic sta-
tus (blue-collar worker, white-collar worker, farmer, private, professional, or other/unspecified), residential area 









Relatives with testicular cancers
Seminoma
Any FDRs Any FDRs
Cases RR 95%CI Cases RR 95%CI
Upper aerodigestive tract 5081 52 0.87 0.66–1.14 14620 33 1.00 0.71–1.40
Stomach 5068 65 0.82 0.65–1.05 10645 17 0.70 0.44–1.13
Colorectum 4813 320 1.09 0.98–1.23 61114 139 0.98 0.83–1.15
Liver 5081 52 0.84 0.64–1.10 11399 24 0.94 0.63–1.40
Pancreas 5051 82 1.25 1.00–1.55 12440 37 1.28 0.93–1.77
Lung 4902 231 1.15 1.01–1.32 45805 106 1.02 0.84–1.24
Breast (female and male) 4713 420 1.10 1.00–1.22 117501 301 1.05 0.94–1.18
Cervix 5087 46 0.87 0.65–1.17 13379 28 0.90 0.62–1.30
Endometrium 5040 93 1.25 1.01–1.53 18113 40 0.92 0.68–1.26
Ovary 5066 67 1.12 0.88–1.43 15417 38 1.01 0.74–1.40
Prostate 4655 478 1.07 0.98–1.18 104535 291 1.16 1.03–1.30
Kidney 5057 76 0.99 0.79–1.24 16116 39 1.05 0.77–1.47
Urinary bladder 5002 131 1.04 0.87–1.24 24864 56 0.98 0.76–1.28
Melanoma 4966 167 1.34 1.15–1.57 41611 127 1.28 1.08–1.53
Skin 5025 108 0.91 0.75–1.10 21948 54 1.07 0.82–1.39
Nervous system 5005 128 1.29 1.08–1.54 32203 83 1.11 0.90–1.38
Thyroid glands 5100 33 1.24 0.88–1.75 8654 22 1.10 0.72–1.67
Endocrine glands 5085 48 0.90 0.68–1.20 14988 29 0.82 0.57–1.18
Connective tissue 5110 23 1.18 0.79–1.78 5558 13 1.02 0.59–1.75
Non-Hodgkin lymphoma 5041 92 1.03 0.84–1.27 23208 55 1.02 0.78–1.33
Hodgkin lymphoma 5108 25 1.48 1.00–2.19 6188 14 1.00 0.59–1.68
Myeloma 5098 35 0.96 0.69–1.34 7042 16 0.97 0.59–1.58
Leukemia 5048 85 1.00 0.81–1.25 23374 44 0.83 0.62–1.11
CUP1 5051 82 1.01 0.81–1.26 15590 37 1.03 0.75–1.42
All (including testis) 2762 2371 1.18 1.12–1.25 699821 1792 1.09 1.04–1.15
Table 3. Risk of cancer in offspring when family members were diagnosed with testicular cancer. Bolding of 
RRs shows that 95%CI does not include 1.00. CUP1 = cancer of unknown primary. FDRs = first degree relatives. 
RR = relative risk. CI = confidence interval.
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(large cities, South Sweden, North Sweden, or unspecified) were added to the model as covariates. SAS version 9.4 
was used to perform the statistical analysis.
Ethical statement. The study was approved by the Ethical Committee of Lund University and the study was 
conducted in accordance with the approved guidelines not requesting informed consent. The study is national 
register-based study on anonymous personal data.
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